Fig. 1 · Structure

Documents & Downloads

Fluocinonide(Vanos)

Cat. No. A11688 CAS 356-12-7
Fluocinonide is a potent glucocorticoid steroid used topically as an anti-inflammatory agent for the treatment of skin disorders.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Fluocinonide(Vanos) Research Summary

This section summarizes 3 in vitro studies of Fluocinonide(Vanos) from 2 published references. In vitro models include mouse Shh-LIGHT2 cells.

Fluocinonide(Vanos) In Vitro Studies

Fluocinonide(Vanos) reduced MTT turnover dose-dependently in mouse subventricular-zone neural stem cells versus control cells, and cyclopamine reversed these effects. Mouse Shh-LIGHT2 cells responded robustly to Fluocinonide(Vanos), with Fluc/Rluc activity as the readout. In the neural stem cell growth study, Fluocinonide(Vanos) did not reproduce the reported clobetasol-associated effect on the rate of cell growth. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

MTT turnover in NSCs were derived from the subventricular zone (SVZ) of 8–12 weeks old (20–24 g) male 129/SV mice

Cell-based study · NSCs were derived from the subventricular zone (SVZ) of 8–12 weeks old (20–24 g) male 129/SV mice [1]

Model: NSCs were derived from the subventricular zone (SVZ) of 8–12 weeks old (20–24 g) male 129/SV mice. Treatment: 0.1–25 μM. Result: fluocinonide (0.1–25 μM): dose-dependent reduction in MTT turnover. These effects were reverted by cyclopamine..

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTT turnoverReported result fluocinonide (0.1–25 μM): dose-dependent reduction in MTT turnover. These effects were reverted by cyclopamine.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.1–25 μM
Exposure duration
1–4 days
Method
cells were exposed to drugs
Vehicle
cell culture media
Co-treatment
Other interventions in this design: EGF 20 ng/mL; bFGF 10 ng/mL; heparin 2 μg/mL. Compound effect isolated by the comparison: vs. control.
Methods and source locations

Compound reported in the paper: Fluocinonide(Vanos); Compound label in the paper: fluocinonide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.3. Clobetasol Increases Proliferation and Dimension of NSCs Neurospheres (S24, S25); 4. Materials and Methods > 4.1. Neural Stem Cell Derivation and Culture (S37, S41); 4. Materials and Methods > 4.2. Shh Pathway Modulation in NSCs (S46, S47, S48); 4. Materials and Methods > 4.3. LDH and MTT Cytotoxicity/Viability Assays (S49, S53, S56); Figure 5 legend (S107, S108)

MTT turnover: MTT turnover; comparator: control cells — 2. Results > 2.3. Clobetasol Increases Proliferation and Dimension of NSCs Neurospheres (S24, S25); 4. Materials and Methods > 4.2. Shh Pathway Modulation in NSCs (S47); Figure 5 legend (S107)

Robust response to fluocinonide in mouse reporter cells

Cell-based study · mouse Shh-LIGHT2 cells [2]

Mouse Shh-LIGHT2 cells were treated with Fluocinonide(Vanos), with Fluc/Rluc activity as the readout. The cells responded robustly to treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fluc/Rluc activityReported result 1 uM fluocinonide: Shh-LIGHT2 cells responded robustly to the hedgehog agonists fluocinonide[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 uM
Method
in DMEM containing 0.5% calf serum
Reported limits
Not stated in the sentences used: schedule, vehicle.
Methods and source locations

Compound reported in the paper: Fluocinonide(Vanos); Compound label in the paper: fluocinonide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Primary screen for chromosome 21 cDNAs that affect SHH signaling (S12, S13); MATERIALS AND METHODS > Luciferase reporter assays (S106); Fig. 2. legend (S160)

Fluc/Rluc activity: Fluc/Rluc activity; comparator: induction media control — RESULTS > Primary screen for chromosome 21 cDNAs that affect SHH signaling (S13); MATERIALS AND METHODS > Luciferase reporter assays (S106); Fig. 2. legend (S160)

Fluocinonide and neural stem cell growth

Cell-based study · NSCs were derived from the subventricular zone (SVZ) of 8–12 weeks old (20–24 g) male 129/SV mice [1]

Neural stem cells derived from the subventricular zone of male mice were exposed to Fluocinonide(Vanos), with untreated cells as the control. Fluocinonide(Vanos) did not reproduce the reported clobetasol-associated effect on the rate of cell growth.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
NSCs rate of cell growth (RCG)Reported result final concentration of 5 μM: clobetasol, but not the other glucocorticoids, was in fact able to double the RCG of NSCs[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM
Exposure duration
1–4 days
Method
cells were exposed to drugs
Vehicle
cell culture media
Co-treatment
Other interventions in this design: EGF 20 ng/mL; bFGF 10 ng/mL; heparin 2 μg/mL. Compound effect isolated by the comparison: vs. untreated control.
Methods and source locations

Compound reported in the paper: Fluocinonide(Vanos); Compound label in the paper: fluocinonide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.3. Clobetasol Increases Proliferation and Dimension of NSCs Neurospheres (S22, S26); 4. Materials and Methods > 4.1. Neural Stem Cell Derivation and Culture (S37, S41, S43); 4. Materials and Methods > 4.2. Shh Pathway Modulation in NSCs (S46, S48); Figure 5 legend (S107, S109, S111)

NSCs rate of cell growth (RCG): NSCs rate of cell growth (RCG); comparator: untreated control — 2. Results > 2.3. Clobetasol Increases Proliferation and Dimension of NSCs Neurospheres (S26); Figure 5 legend (S109)

Specifications

Manufacturer Adooq Bioscience
CAS Number 356-12-7
Formula C26H32F2O7
Molecular Weight 494.52
SMILES
CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3C[C@@H](C5=CC(=O)C=C[C@@]54C)F)F)O)C)OC(O2)(C)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 94 mg/mL (190.08 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Fluocinonide(Vanos) Research References

  1. [1] Vicario N, Bernstock JD, Spitale FM, et al. Clobetasol Modulates Adult Neural Stem Cell Growth via Canonical Hedgehog Pathway Activation. Int J Mol Sci (2019). PMID: 31018557 DOI: 10.3390/ijms20081991 Source material
  2. [2] Moyer AJ, Fernandez FX, Li Y, et al. Overexpression screen of chromosome 21 genes reveals modulators of Sonic hedgehog signaling relevant to Down syndrome. Dis Model Mech (2023). PMID: 36995257 DOI: 10.1242/dmm.049712 Source material

Added to your cart

View Cart Checkout
Loading...